Expedited FDA & Global Programs
Accelerated
Pathways
Leaders in Expedited Program Strategy
for Drugs & Biologics
Leaders in Expedited Program Strategy
for Drugs & Biologics
For a serious disease with unmet need, the right FDA designation can move approval years closer: earlier and more frequent agency contact, rolling review, a surrogate-endpoint route to market, and a review clock cut from ten months to six. None of it is automatic. Each program turns on its own statutory bar, opens in its own request window, and leaves behind obligations that outlast the press release. We help sponsors win the designations they actually qualify for, stack them in the right order, and carry what comes attached.
Breakthrough, Fast Track, and priority routes get you there sooner, only if the evidence keeps pace.
Expedited status is not one thing. It is a toolkit of distinct designations, each turning on its own standard of evidence and granting its own advantage. They stack, and the art is requesting the combination your data can actually support.
Opens a working dialogue with the division and lets you submit your application in pieces as they are ready, rather than all at once.
Puts senior reviewers and organizational commitment behind your program, with every Fast Track feature plus hands-on development advice.
Reaches patients on an endpoint reasonably likely to predict benefit, years before an outcomes trial could read out, against a binding confirmatory-trial commitment.
The regenerative-medicine equivalent of Breakthrough, written for cell therapies, gene therapies, and tissue-engineered products.
Compresses FDA's review of the marketing application from ten months to six once the file is in, the payoff waiting at the finish line.
Not a speed program but a stacking one: exclusivity, fee waivers, and tax credits that layer on top of any expedited route you take.
Breakthrough, Fast Track, Accelerated Approval, RMAT — distinct instruments, each turning on its own standard of evidence.
Most expedited programs must be requested at a particular point in development, when your evidence is strong enough to qualify but early enough to still benefit. Ask too soon and you are denied; too late and the advantage is already spent. This is where each request belongs.
Qualify too early and you are denied; file too late and the fastest route has already closed.
Requestable before your IND. It stacks with everything downstream and starts the exclusivity clock early.
Nonclinical or early clinical evidence of unmet need is enough to open rolling review and frequent contact.
A preliminary clinical signal of substantial improvement unlocks intensive senior FDA engagement.
Agree the surrogate endpoint and the confirmatory trial with FDA before the pivotal design is locked.
Requested with the marketing application itself, cutting the review clock right at the finish line.
Half the work is persuading FDA to grant the status. The other half begins the moment they do, because every expedited program hands you obligations along with the advantage.
A designation request is a persuasion document, not a form. We assemble the clinical, nonclinical, and mechanistic case that your product meets a specific statutory standard, backed by exactly the right evidence and no noise, and write the argument the division needs in order to say yes.
Designations create commitments: confirmatory trials, post-marketing requirements, intensified interaction, and the standing risk of losing the status if the data does not hold. We build the plan that captures the benefit while meeting every obligation the program attaches.
Accelerated Approval reaches patients early on a promise: that a confirmatory trial will verify the benefit the surrogate predicted. FDA now enforces that promise, and a confirmatory trial that stalls or fails can pull an approved product back off the market.
Early access is granted against a confirmatory trial the agency now expects to be already running.
The head start a surrogate endpoint can buy over a full outcomes trial, the entire reason the pathway exists.
FDA's authority, strengthened in 2023, to require confirmatory trials be underway at approval and to withdraw faster when they fail.
When the confirmatory-trial strategy has to be designed, not after approval when the leverage is already gone.
The major agencies run their own expedited programs, and pursued in isolation they generate conflicting commitments. Sequenced together, each designation strengthens the case for the next.
EMA's priority-medicines scheme: early dialogue, a rapporteur appointed at the start, and a path toward accelerated assessment for medicines addressing an unmet need.
The MHRA Innovative Licensing and Access Pathway pairs an innovation passport with a target development profile and tools that compress time to UK patients.
FDA-led concurrent review of oncology products across partner regulators, so one dossier can win near-simultaneous decisions in several countries.
A US designation should buy speed in the next market, not contradict it. The expedited routes are architected to align.
None of these come from weak science. They come from treating a designation as a trophy instead of an instrument with a bar, a window, and a bill attached.
Optimizing for the prestige of Breakthrough when Fast Track was the achievable, sufficient route, and burning a cycle on a denial the data never supported.
Requesting a designation after the evidence that would have qualified you is already public, or after the stage where the benefit still meaningfully applies.
Taking Accelerated Approval without a confirmatory trial designed, powered, and enrolling, then watching the label come under threat when it slips.
A request that oversells the data. Reviewers remember, and the credibility you spend does not come back for the review that actually decides approval.
Winning FDA speed while EMA and MHRA timelines drift, so the global launch fragments instead of compounding into a coordinated rollout.
Treating the grant as the finish line. The advantage is realized only in the development and filing decisions that follow, not the announcement.
Expedited strategy is judgment built from having done it: knowing which program a division will actually grant, how to frame the request, and what the commitment costs downstream. Your leads are senior regulatory practitioners who have secured Fast Track, Breakthrough, RMAT, and Accelerated Approval, and run the confirmatory programs that keep them.
We know how specific FDA divisions read these requests, and which designation is realistic before you spend a cycle finding out.
We match the request to the data you actually have, so the case is persuasive rather than aspirational.
Small molecule, biologic, and the advanced therapies RMAT was written for, each with its own path through the programs.
We stay past the grant, running the confirmatory trials and post-marketing commitments that keep a designation from unraveling.
A designation strategy touches the rest of the regulatory program. These are the services expedited sponsors reach for most.
The meetings where a designation is discussed, granted, or lost, prepared so your scarce agency interactions land.
Explore Meetings →Expedited timelines compress CMC hardest. The manufacturing story, built to keep pace with an accelerated clinical program.
Explore CMC →PRIME, ILAP, and Project Orbis sequenced with FDA, so speed in one region compounds into the next.
Explore Global →Tell us about your asset, your indication, and where your data stands. We'll assess which expedited programs you qualify for and match you with a senior regulatory lead, with a response within one business day. All inquiries are strictly confidential.
